Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
About this episode
Richard Pops discusses his career and Alkermes' advancements in orexin biology for treating sleep disorders.
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
More episodes of The Long Run with Luke Timmerman
- Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
- Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
- Ep196: Otello Stampacchia on Europe's Biotech Crisis
- Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
- Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
- Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
Explore listener stats, chart rankings, contacts and more on the The Long Run with Luke Timmerman podcast page.